- Home
- ACIU vs BDTX Comparison
ACIU vs BDTX Comparison
Compare ACIU & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- BDTX
- Stock Information
- Founded
- ACIU 2003
- BDTX 2014
- Country
- ACIU Switzerland
- BDTX United States
- Employees
- ACIU N/A
- BDTX N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACIU Health Care
- BDTX Health Care
- Exchange
- ACIU Nasdaq
- BDTX Nasdaq
- Market Cap
- ACIU 213.3M
- BDTX 181.4M
- IPO Year
- ACIU 2016
- BDTX 2020
- Fundamental
- Price
- ACIU $2.48
- BDTX $3.19
- Analyst Decision
- ACIU Strong Buy
- BDTX Strong Buy
- Analyst Count
- ACIU 2
- BDTX 6
- Target Price
- ACIU $10.00
- BDTX $12.50
- AVG Volume (30 Days)
- ACIU 132.0K
- BDTX 805.6K
- Earning Date
- ACIU 11-04-2025
- BDTX 11-04-2025
- Dividend Yield
- ACIU N/A
- BDTX N/A
- EPS Growth
- ACIU N/A
- BDTX N/A
- EPS
- ACIU N/A
- BDTX 0.25
- Revenue
- ACIU $36,362,036.00
- BDTX $70,000,000.00
- Revenue This Year
- ACIU N/A
- BDTX N/A
- Revenue Next Year
- ACIU $1,022.98
- BDTX N/A
- P/E Ratio
- ACIU N/A
- BDTX $12.74
- Revenue Growth
- ACIU 86.71
- BDTX N/A
- 52 Week Low
- ACIU $1.43
- BDTX $1.20
- 52 Week High
- ACIU $3.98
- BDTX $6.23
- Technical
- Relative Strength Index (RSI)
- ACIU 64.11
- BDTX 60.41
- Support Level
- ACIU $2.12
- BDTX $2.56
- Resistance Level
- ACIU $2.35
- BDTX $3.43
- Average True Range (ATR)
- ACIU 0.13
- BDTX 0.17
- MACD
- ACIU 0.04
- BDTX 0.04
- Stochastic Oscillator
- ACIU 95.74
- BDTX 67.57
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.